Page 1 of 6 -1-

BIOPHARM OF FLORIDA

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)

Studie aus Japan in den 90iger Jahren!
These are data provided by Dr. Kamataro Sano of Sano Surgical Hospital, 22-4. Aosawa 2
Chome, Kofu, Japan.

All of the patients have been undergoing Dr. Sano's special treatments in addition to Dr.
Goldberg`s 10 points therapy, CDA-II, which included urine therapy , diet therapy, large
dosage of vitamin C (20-40g/day),

and Vitamin B17 Amygdalin- (3-12 g/day).

The dosage of CDA-II was 200 c.c.(10g), which was mixed with vitamin C and 500 c.c. of
Ringer solution to be administered by i.v. infusion.

In case of capsule, the dosage was 15 capsules a day.

Of 50 patients treated 47 patients were regarded invaluable, who have been treated with CDA-
II for more than 4 weeks. In the surgery column O means yes, and x means no.

Summary of Clinical Efficacy of CDA-II Conducted at the First Affiliated Hospital of Anhui
Medical University
Clinical Efficacy Cases %
Complete remission 2 6
Partial remission 6 19
Stabile 15 47
Ineffective 9 28
All patients were treated with CDA-II by i.v. infusion only. The dosage was 200cc(10g) per
day, which was mixed with 300cc of Ringer solution. Of 47 patients treated 32 patients were
considered evaluable for undergoing treatment over 4 weeks. 15 patients gave up treatment
for various reasons.
Adverse Effects of CDA-IIG
Adverse Effects Cases %
Venous irritation 7 17
Dizziness 2 5
Abdominal gas 1 2
Fever 2 2
Nausia 1 2
41 cases among 47 cases treated were considered invaluable for undergoing treatment over 3
weeks.
Symptomatic Adverse Clinical
No. Patient Sex Age Diagnosis Treatment Period
Improvement Effects Efficacy
Oesophagus cancer
95.10.25-
1 dp male 73 post radiotherapy Progressive disease None Ineffective
95.11.30
recurrence
Lung cancer(upper Slight
2 male 64 95.11.7-96.1.2 None Stabile
right) metastasized improvement
Page 2 of 6 -2-
BIOPHARM OF FLORIDA

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)

Studie aus Japan in den 90iger Jahren!
to the subclavian
bone
Cervical cancer
Marked decrease
metastasized to the
95.10.20- of tumour size and Venius Partial
3 L^ female 58 vulva and
95.12.10 improvement of irritation remissions
abdominal-vaginal
symptom
joint
Tumours
disappearing, also
disappearance of Dizziness
Non Hodgkin Complete
4 H male 72 95.11.2-96.4.8 pressure due to Venous
lymphoma, stage 3 remission
tumours, general irritation
conditions greatly
improved
Esophagogastric
95.11.11- Passes away due to
5 B male 70 cancer with wide None ----
95.11.20 massive bleeding
spread metastasis
Malignant Progressive disease
6 male 50 95.10.25-95.12.6 Flush Ineffective
lymphoma, stage 4 to end in death
Lung cancer, stage
General conditions
7 male 40 4, metastasized to 95.11.7-95.12.23 Nausea Stabile
improved
the spine
Lung cancer post
Fever,
8 o male 64 surgery metastasis 95.11.8-95.11.28 Progressive disease Ineffective
dizziness
to the chest spine
Nasophargngeal
carcinoma 95.11.21-
9 [M male 30 Progressive disease None Ineffective
metastasized to the 95.12.19
bone and lung
Esophagus cancer,
post radiotherapy
Tumour in the lung
10 } male 60 recurrence, 96.7.18-96.8.22 None Ineffective
increasing
metastasized to the
lung
Malignant 95.11.15-
11 Z male 32 No change None ----
lymphoma, stage 3 95.12.10
Prostate cancer
Patient declines
12 male 78 metastasized to the 95.11.25-95.12.4 None ----
further treatment
bone, stage 4
Esophagus cancer,
Stabile and slow
13 o male 67 post radiotherapy 95.11.20-96.1.2 None Stabile
improvement
recurrence
Decrease of ascites
Late stage
fluid and
hepatoma with Partial
14 male 50 96.1.12-96.3.10 abdominal None
large volume of remission
distension, tumour
ascites fluid
stabilized
Lung cancer Seems to improve
15 I male 70 96.1.25-96.2.19 None ----
metastasized the first two weeks,
Page 3 of 6 -3-
BIOPHARM OF FLORIDA

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)

Studie aus Japan in den 90iger Jahren!
outside chest but deteriorates
afterward
Kidney cancer, post
16 w male 58 surgery metastasis 96.4.10-96.5.2 No change No ----
to the lung
Lung cancer
Stabile but not
17 male 72 multiple metastasis 96.2.2-96.3.4 None Stabile
much improvement
to the spine
Late stage
Venous
18 d female 60 hepatoma with 96.7.2-96.7.22 Progressive disease ----
irritation
ascites
Lower larynx
cancer, post
19 s male 46 96.7.29-96.8.29 Progressive disease None Ineffective
surgery metastasis
to the neck
Tumours
disappearing,
Lung cancer(upper 96.3.25-96.5.18
general condition Venous Complete
20 u male 76 left) metastasized 96.10.10-
greatly improved, irritation remission
to the chest wall 96.11.10
increase of appetite
and body weight
Lung cancer, left Slight
Stabile and slow
21 male 54 side, metastasized 96.2.30-96.3.30 venous Stabile
improvement
to the brain irritation
Malignant glioma,
post surgery
22 ^ female 48 96.7.2-96.7.24 No change None ----
metastasis to the
lung
Lung cancer left
Venous
23 male 62 side, metastasize to 96.5.22-96.7.2 Progressive disease Ineffective
irritation
the lumbar spine
Esophagus cancer,
post surgery
24 male 62 96.7.10-96.8.2 No change None ----
metastasis to the
liver
Lung cancer, post
surgery wide Stabile and
25 u male 66 96.5.12-96.6.28 None Stabile
spread to the chest improving
and brain
Late stage lung
Stabile and Abdominal
26 male 46 cancer with wide 96.10.6-96.11.2 Stabile
improving distention
spread metastasis
Esophagus cancer
96.11.20- Stabile and slight
27 G~ male 56 metastasized to the None ----
96.12.10 improvement
liver
Lung cancer, left Tumours greatly
96.11.20- Partial
28 BX female 70 side, metastasized shrinked, symptom None
96.12.20 remission
to the lumbar spine greatly improved
Page 4 of 6 -4-
BIOPHARM OF FLORIDA

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)

Studie aus Japan in den 90iger Jahren!
Larynx cancer, post Tumours greatly
96.11.10- Venous Partial
29 i male 50 surgery metastasis shrinked, symptom
96.12.20 irritation remission
to the lung greatly improved
Colon cancer with
96.12.10- Stabile and slight
30 \ male 47 wide spread None ----
96.12.30 improvement
metastasis
Esophagus cancer
Stabile and
31 male 74 metastasized to the 96.12.10.97.1.8 None Stabile
improving
lung
Good symptomatic
Cervical cancer improvement,
Partial
32 dC female 42 with wide spread 96.11.2-97.1.2 becoming more None
remission
metastasis energetic, Tumours
stabilized
Lung cancer
Stabile and
33 female 61 metastasized to the 96.10.12.96.12.10 None Stabile
improving
liver
Brain stem tumour,
Stabile, quality of
34 \ female 20 post radiotherapy 96.11.10-97.1.2 None Stabile
life improved
recurrence
Rectal cancer, post
surgery wide
35 i male 38 spread metastasis 96.12.28-97.2.18 Progressive disease None Ineffective
to the abdominal
cavity
Lung cancer, stage 96.10.15- Stabile and
36 BT male 54 None Stabile
4 96.11.27 improving
Nasopharyngeal
carcinoma, post Stabile and
37 Q male 38 96.12.20-967.2.5 None Stabile
radio therapy improving
metastasis
Lung cancer(right
Stabile and
38 \y male 64 side), post surgery 96.11.7-96.12.7 None Stabile
improving
metastasis
Stomach cancer
96.11.20- Patient declines
39 B male 56 metastasized to the None ----
96.12.15 further treatment
liver
Patient declines
Esophagus cancer
96.11.31- further treatment
40 ] male 59 metastasized to the None ----
96.12.14 because of lack of
lung
improvement
Decrease of
Rectal cancer, post tumour size and Partial
41 T male 68 96.12.8-97.1.20 None
surgery recurrence pain, increase of remission
appetite
Overian cancer, Patient can not
42 ^ female 57 post surgery wide 97.1.2-97.1.22 afford further None ----
spread metastasis treatment
Page 5 of 6 -5-
BIOPHARM OF FLORIDA

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)

Studie aus Japan in den 90iger Jahren!
Malignant
melanoma with
43 male 49 96.12.5-97.1.15 Progressive disease None Ineffective
wide spread
metastasis
Lung and bile duck 96.10.20-
44 male 65 Progressive disease None ----
cancer 96.10.30
Stomach cancer
96.12.10-
45 female 36 metastasized to the Progressive disease None ----
96.12.24
liver, jaundice
Lung cancer, lower Stabile and
46 male 48 97.1.31-97.3.1 None Stabile
right side improving
Sarcoma of the
smooth mustle of Stabile and
47 P male 36 97.2.16-97.3.26 None Stabile
the back side of improving
abdominal cavity

Summary of Clinical Efficacy of CDA-II Conducted in Japan

Clinical
Anticancer Effect Symptomatic Improvement Subtotal Percentage
Efficacy
Complete Total eradication of Dramatic increase of appetite, also dramatic
4 %
remission Tumours improvement on respiration, pain, and cough
Partial Decrease of tumour Good appetite, also good improvement on
16 34%
remission size over 50% respiration, pain, and cough
Decrease of tumour Recovery pf appetite, also noticeable
Imporvement 13 28%
size less than 50% improvement on respiration, pain, and cough

No change No significant change of symptoms 8 17%

Progressive Tumours imcreasing Worsening to result in death 5 11%

Total 47 100%

All of the patients have been undergoing Dr. Sano's special treatmens in addition to CDA-II,
which included urine therapy , diet therapy, large dosage of vitamin C (20-40g/day), and B17
(3-12 g/day). The dosage of CDA-II was 200 c.c.(10g), which was mixed with vitamin C and
500 c.c. of Ringer solution to be administered by i.v. infusion.
In case of capsule, the dosage was 15 capsules a day.
Of 50 patients treated 47 patients were regarded evaluable, who have been treated with CDA-
II for more than 4 weeks.
In the surgery column O means yes, and x means no.

Adverse Effects of CDA-II

Summary of Clinical Efficacy of CDA-II Dr. Kamataro Sano
cases %
http://www.brave-souls.com/learn-from-others/| Home Adverse Effects
Vinous irritation 17 34
Vinous thrombosis 4 8